公开(公告)号：US11931554B2

公开(公告)日：2024-03-19

申请号：US17408908

申请日：2021-08-23

申请人： ICON BIOSCIENCE, INC.

发明人： Cathy Ann Gerlett

IPC分类号： A61M5/315 ,  A61M5/28

CPC分类号： A61M5/31541 ,  A61M5/28 ,  A61M5/31525 ,  A61M5/31573 ,  A61M5/31578 ,  A61M5/3159

摘要： A kit is disclosed for accurately loading a small volume dose of a medication within a syringe and for delivering the small volume dose of the medication at a treatment site. The kit generally includes a loading and delivery system in accordance herewith, a syringe, and a medication. The loading and delivery system includes a syringe delivery ring and a syringe loading guide, which may be used for example, to administer a small volume dose of a medication at the end of an ocular surgery.

公开(公告)号：US09814773B2

公开(公告)日：2017-11-14

申请号：US14124631

申请日：2012-06-11

申请人： Vernon G. Wong ,  Louis L. Wood ,  Carol Wood ,  Glenn T. Huang

发明人： Vernon G. Wong ,  Louis L. Wood ,  Glenn T. Huang

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K47/14 ,  A61K47/20 ,  A61K47/34 ,  A61K38/17 ,  A61K9/08

CPC分类号： A61K39/39541 ,  A61K9/0024 ,  A61K9/0051 ,  A61K9/08 ,  A61K38/1709 ,  A61K47/14 ,  A61K47/20 ,  A61K47/34

摘要： The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 μL to 100 μL of the formulation provides for sustained release of the agent for at least 14 days.

公开(公告)号：US10159683B2

公开(公告)日：2018-12-25

申请号：US16018931

申请日：2018-06-26

申请人： ICON BIOSCIENCE, INC.

发明人： Vernon G. Wong ,  William S. White ,  Mae W. Hu ,  Glenn T. Huang ,  Faina Karasina

IPC分类号： A61K31/573 ,  A61K47/14 ,  A61K9/00

摘要： The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.